Trial Profile
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Two Period, Crossover Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2021
Price :
$35
*
At a glance
- Drugs Reldesemtiv (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 05 Oct 2018 According to an Astellas Pharma media release, primary endpoint (Change from period baseline in Constant Work Rate (CWR) endurance time) has not been met.
- 26 Jul 2018 According to a Cytokinetics media release, results from this trial are expected in Q3 2018.
- 20 Jun 2018 Status changed from active, no longer recruiting to completed.